BioSpace News Archive

Therap Services offers several Health Tracking tools as one of the features of the comprehensive Electronic Health Records (EHR) solution for providers in Home and Community-Based Services (HCBS) and the broader Long-Term Services and Supports (LTSS) settings.

Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of oncology, is excited to announce it has expanded its Strategic Alliance Partnership (SAP) program with the addition of the Kentucky Society of Clinical Oncology and Virginia Cancer Specialists, strengthening its position in the oncology space

CORAT Therapeutics GmbH obtained the regulatory approval as well as the favorable opinion from the central ethics committee to conduct the clinical phase Ib/II trial with its antibody COR-101 against COVID-19.

CytoSeek Ltd, a discovery-stage biotech company developing the next generation of cell therapies to treat cancer, is excited to announce today the completion of a £3.57M ($5M) funding round.

Pliant Therapeutics, Inc. (Nasdaq: PLRX) (the Company), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter and full year 2020 financial results.

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three and twelve months ended December 31, 2020.

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its financial results for the fourth quarter and year ended December 31, 2020.

Insulet to Host an Investor Webcast to Discuss Omnipod ® 5 Pivotal Data Omnipod 5 is the world’s first tubeless, wearable automated insulin delivery system that continuously adapts insulin delivery based on glucose levels and trends

Vicarious Surgical Inc., a next-generation robotics technology company seeking to improve both cost and efficiency of surgical procedures as well as patient outcomes, today announced the appointment of William J. Kelly, CPA as the Company’s Chief Financial Officer, and June M. Morris, Esq. as General Counsel and Chief Legal Officer, effective March 1, 2021.

Helix BioPharma Corp. an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal second quarter ended January 31, 2021.